
    
      PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2
      treatment arms.

      Arm I: Patients receive growth hormone subcutaneously (SC) daily for 1 year during the first
      year only.

      Arm II: Patients receive growth hormone SC daily for 1 year during the second year only.

      Quality of life is assessed at baseline and then every 6 months for 2 years.
    
  